Research Funding

Grant Title Grantor Amount Award Date
Lakshmi Rajagopal, PhD
Role of an ornithine rhamnolipid pigment in GBS virulence - R01 AI112619 NIH/NIAID $250,000 annual direct costs July 1, 2014 - June 30, 2019
Lisa M. Frenkel, MD
"Evaluation of mHealth strategies to optimize adherence and efficacy of PMTCT/ART" - R01 HD080460 (PI: John-Stewart) NIH $11,393 subcontract annual direct costs May 1, 2014 - April 30, 2019
Lisa M. Frenkel, MD
"A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART" - R01 AI110375 NIH $250,000 annual direct costs May 1, 2014 - April 30, 2019
Lisa M. Frenkel, MD
Mechanisms of Formation and Persistence of Active HIV Reservoirs - R01 AI111806 (PI: Mullins) NIH $114,390 subcontract annual direct costs April 1, 2014 - March 31, 2019
Jane L. Burns, MD
Prevalence and Clinical Significance of S. aureus small-colony variants - HOFFMA14A0 (PI: Burns and Hoffman) Cystic Fibrosis Foundation Therapeutics $109,481 Burns annual direct costs April 1, 2014 - March 31, 2017
Timothy Rose, PhD
Point-of-care diagnosis and surveillance of known and emerging influenza viruses - R01 AI111303 NIH/NIAID $855,731 annual directs March 15, 2014 - Feb. 28, 2019
Thor A. Wagner, MD
"Mechanisms of Formation and Persistence of Active HIV Reservoirs" - R01 AI111806 (PI: Mullins) NIH $10,720 subcontract annual direct costs March 15, 2014 - Feb. 28, 2019
Lisa M. Frenkel, MD
"International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group" Virology Lab - UM1 AI106716 (PI: Aldrovandi) NIH $95,547 annual direct costs Jan. 1, 2014 - Nov. 30, 2020
Jane L. Burns, MD
Long Term Outcomes after Eradication of Pseudomonas aeruginosa among Children Enrolled in the EPIC Clinical Trial - #CTBM100CUSNC01T (PI: Hamblett) Novartis $34,426 annual direct costs Dec. 15, 2013 - Dec. 15, 2015
Lakshmi Rajagopal, PhD
Environmental signals that regulate GBS virulence - R21 AI109222 NIH/NIAID $150,000 annual direct costs Sept. 1, 2013 - Aug. 31, 2015
Jane L. Burns, MD
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis - UM1 HL119073 (PI: Goss) $55,495 Burns' annual direct costs Sept. 1, 2013 - June 30, 2016
Lakshmi Rajagopal, PhD
Eukaryotic-type signaling mediates two-component regulation of GBS virulence - R56 AI070749-06A1 NIH/NIAID $247,362 annual direct costs June 11, 2013 - Dec. 31, 2014
Lisa M. Frenkel, MD
"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: Holmes) NIH $95,547 annual direct costs June 1, 2013 - May 31, 2015
Marta Bull, PhD
"University of Washington Center for AIDS Research" (CFAR) - P30 AI027757 (PI: King Holmes) NIH $11,528 subcontract annual direct costs June 1, 2013 - May 31, 2015
Janet A. Englund, MD
Clinical Significance of rhinovirus Seattle Children's Hospital Clinical Translational Research Center Dec. 20, 2012 - Sept. 30, 2013
Danielle M. Zerr, MD, MPH
Frequency and Duration of Intestinal Carriage and Bacterial Evolution Over Time in Pediatric Patients with Resistant Enterobacteriaceae Infections Children's Research Institute/Translational Research Ignition Projects Program $50,000 Dec. 12, 2012 - Sept. 30, 2013
Jane L. Burns, MD
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Repeat-Dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa KaloBios Pharmaceuticals, Inc. $45,032 total direct costs Oct. 10, 2012 - Oct. 9, 2014
Danielle M. Zerr, MD, MPH
Impact of chlorhexidine bathing on reducing infections in children with cancer NIH/NCI $410,000 Aug. 1, 2012
Lakshmi Rajagopal, PhD
GBS mediated in utero fetal injury - R01 AI100989 (Co-PI with Kristina Adams Waldorf) NIH/NIAID $499,906 annual direct costs July 1, 2012 - June 30, 2017
Lisa M. Frenkel, MD
"Drug-resistance testing in Kenya to improve ART suppression of HIV replication" (PEPFAR) - R01 AI100037 NIH $695,729 annual direct costs June 3, 2012 - May 31, 2015
Janet A. Englund, MD
RSV surveillance and antibody levels in Southeast Asia PATH May 2012 - June 2014
Lisa M. Frenkel, MD
"Academic Pediatric Infectious Disease" - T32 HD007233 NIH $277,930 annual direct costs May 1, 2012 - April 30, 2017
Jane L. Burns, MD
Lab Services - Grifols Protocol# T6005-201 Grifols Therapeutics, Inc. April 10, 2012 - April 10, 2014
Scott J. Weissman, MD
Differences in infecting and colonizing Enterobacteriaceae from short-course vs standard therapy of pediatric UTI - R21AI099930 NIH/NIAID $125,000 annual DC April 1, 2012 - Feb. 28, 2015
Jane L. Burns, MD
Persistent MRSA Eradication Protocol - #PMEP11K1 (PI: Dasenbrook) CFFT $37,240 subcontract annual direct costs Jan. 1, 2012 - Dec. 31, 2014
Thor A. Wagner, MD
Systematic High-Throughput Screening of B-cell Repertoires to Identify Antibodies Specific for HIV-Infected Cells Bill and Melinda Gates Foundation $ Nov. 1, 2011 - April 30, 2013
Janet A. Englund, MD
New Vaccine Surveillance Network CDC Aug. 1, 2011 - July 31, 2015
Timothy Rose, PhD
Oral pathogenesis and host interactions of KSHV infection - P01 DE021954 NIH/NIDCR $993,231 + $120,000 annual directs June 7, 2011 - April 30, 2016
Serge Barcy, PhD
Oral pathogenesis and host interactions of KSHV infection - P01 DE021954 (Rose) NIH/NIDCR $993,231 annual directs June 1, 2011 - April 30, 2016
Lisa M. Frenkel, MD
"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01AI091550. NIH/NIAID $254,817 annual direct costs Jan. 21, 2011 - Dec. 31, 2015
Marta Bull, PhD
"HIV-1 evolution in the female genital tract and trafficking in the blood" - R01 AI091550 (PI: Frenkel) NIH $254,817 annual direct costs Jan. 21, 2011 - Dec. 31, 2015
Lisa M. Frenkel, MD
"Immunologic and Virologic Events in Early HIV Infection" (SEAPIP) - P01 AI057005 (Mullins). NIH $101,000 annual direct costs July 15, 2010 - June 30, 2015
Jane L. Burns, MD
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis - P30 DK089507 (PI: Ramsey & Greenberg) NIH $25,749 Burns' annual direct costs July 6, 2010 - May 31, 2015
Danielle M. Zerr, MD, MPH
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections NIH/NIAID $437,668 July 1, 2010
Scott J. Weissman, MD
Resistance and relatedness: Molecular features of Klebsiella pneumoniae as a colonizer and pathogen in pediatric patients in Seattle, WA Institute of Translational Health Sciences/UW June 3, 2010 - April 30, 2012
Scott J. Weissman, MD
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections - R01 AI083413 (Co-PI with Zerr) NIH/NIAID $420,236 annual DC June 1, 2010 - May 31, 2015
Jane Burns, MD
Safety and efficacy of aztreonam Gilead Sciences Jan. 12, 2010 - Jan. 12, 2015
Thor A. Wagner, MD
HIV Persistence Despite Therapy due to Proliferation of Infected Cells Fraternal Order of Eagles Oct. 1, 2009 - Sept. 30, 2014
Jane Burns, MD
Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment NIH $ Sept. 11, 2009 - July 31, 2014
Danielle Zerr, MD, MPH
Impact of Daily Bathing with Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit Sage Products, Inc. $100,000.00 Sept. 1, 2009
Danielle Zerr, MD, MPH
HHV-6 and CNS disease following stem cell transplant NIH/NIAID $278,321.00 Sept. 1, 2009
Danielle Zerr, MD, MPH
National surveillance of emerging MDR in pediatric Enterobacteriaceae infections NIH/NIAID $378,005.00 Aug. 11, 2009
Timothy Rose, PhD
POC molecular method for detection of known and emerging respiratory viruses NIH/NIDCR $300,885.00 July 1, 2009
Danielle Zerr, MD, MPH
Infection Control of Keyboards (ICK) Study: A Randomized, Blinded, Multi-Center Study of Ultraviolet Light Decontamination Vioguard LLC $114,000.00 June 1, 2009
Janet A. Englund, MD
Operation of a Facility for the Study of Infectious Agents, Vaccines, and Antimicrobials NIH/ Subsite of Johns Hopkins April 7, 2009 - April 6, 2013
Lisa M. Frenkel, MD
"Low-frequency HIV-1 Drug Resistance Mutations in Primary HIV-1 Infection" - R01 AI078802 (Steckler) NIH $61,594 annual direct costs April 1, 2009 - June 30, 2015
Janet A. Englund, MD
Maternal Immunization to protect the Mother and Neonate Bill and Melinda Gates Fndn Jan. 2009 - Dec. 2014
Thor Wagner, MD
Novel microcapillary immunoassay methodology to enable point-of-care infant HIV-1 diagnosis Seattle Children’s Hospital Jan. 1, 2009
Danielle Zerr, MD, MPH
Emerging MDR in pediatric Enterobacteriaceae infections CCTR Pediatric Pilot Award $20,000.00 Dec. 1, 2008
Thor Wagner, MD
Persistent HIV-1 Replication in the Respiratory Tract Despite Antiretroviral Treatment NIH-NIAID Sept. 1, 2008 - Nov. 30, 2013
Thor A. Wagner, MD
Improving Pediatric HIV-1 Diagnostics in an Effort to Avoid Antiretroviral Treatment Failure in Tamilnadu, India Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene July 1, 2008 - June 30, 2014
Ann Melvin, MD
Bone mineral density in tenofovir-exposed infants and young children Gilead Sciences Phase4 program $47,943.00 June 23, 2008
Ann Melvin, MD
Bioethics core NIH Cooperative Agreement $1,583,701.00 June 1, 2008
Scott J. Weissman, MD
Multi-drug resistance and virulence patterns in canine and feline urinary E. coli American College of Veterinary Medicine Jan. 1, 2008 - March 31, 2011
Ann Melvin, MD
International and Domestic Pediatric and Maternal HIV Studies Coordinating Center NIH $659,107.00 Dec. 16, 2007
Lisa M. Frenkel, MD
"International and Domestic Pediatric and Maternal HIV Studies Coordinating Center" - NO1-DK-8-0001 (Melvin). NIH $11,360 annual direct costs Dec. 16, 2007 - Nov. 30, 2014
Timothy Rose, PhD
Viral and cellular factors involved in KSHV entry in cells of the oral mucosa NIH/NIDCR $1,125,000.00 Aug. 15, 2007
Timothy Rose, PhD
Herpesvirus latency and reactivation in macaque models of human disease NIH/NCRR $1,680,995.00 July 1, 2007
Lisa M. Frenkel, MD
"Occurrence and Outcome of Dual HIV-1 Infection" - R37 AI047734 (Mullins) NIH $4,987 annual direct costs July 5, 2005 - March 31, 2015
Ann Melvin, MD
Reservoirs of Drug-Resistant HIV-1 – US-India Collaborative Research Supplement NIH $58,907.00 March 1, 2005
Danielle Zerr, MD, MPH
HHV-6 and CNS disease following stem cell transplant NIH/NIAID $1,250,000.00 July 1, 2004
Jane Burns, MD
Translational Therapeutics Development Center - #GIBSON09YO (PI: Gibson) Cystic Fibrosis Foundation Therapeutics $166,400 annual direct costs April 1, 2004 - Dec. 31, 2014
Jane L. Burns, MD
Therapeutics Development Network Coordinating Center (CFFT Infrastructure 2014-2015) (PI: Ramsey) CFFT $11,443 Burns' annual direct costs April 1, 2004 - March 31, 2015
Danielle Zerr, MD, MPH
Viral Pathogens and First Time Seizures in the Setting of Illness Private Donation $60,000.00 June 30, 2003
Jane L. Burns, MD
Therapeutic Development Center Microbiology Core Laboratory - #BURNS03Y3 Cystic Fibrosis Foundation Therapeutics $112,315 annual direct costs April 1, 2003 - Dec. 31, 2014
Charles Smith, PhD
Short Term Research Training in Pediatrics for Medical Students unknown $182,260.00 May 1, 1993